AQST News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AQ

Mkt Cap

$472.9M

Volume

5.08M

Next Earnings

November 4th

Loading chart

AQ

AQSTAquestive Therapeutics, Inc. Common Stock

AQST

Pay with—

Available Balance0.00

AQ

Mkt Cap

$509.6M

Volume

5.08M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film for treating Type I allergic reactions and anaphylaxis. The FDA assigned a PDUFA goal date of March 16, 2027, classified as a Class 2 response. If approved, Anaphylm would be the first and only oral rescue medication for severe allergic reactions. The company is also advancing its Canadian regulatory submission planned for Q4 2026.GlobeNewswire Inc. · Oct 15, 2026

AQST DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQSTRosen Law Firm reminds investors in Aquestive Therapeutics (AQST) who purchased securities between June 16, 2025 and January 8, 2026 of the May 4, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application for Anaphylm, specifically concealing human factors issues related to packaging, use, administration, and labeling of its sublingual film product.GlobeNewswire Inc. · May 2, 2026

Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Atara Biotherapeutics alleging securities fraud. The complaint claims the company made false statements about manufacturing issues and deficiencies in the ALLELE study that would likely prevent FDA approval of tabelecleucel. Investors who purchased Atara securities between May 20, 2024 and January 9, 2026 may be eligible to join the case.GlobeNewswire Inc. · Apr 30, 2026

Bragar Eagel & Squire, P.C. Reminds Aquestive Therapeutics, Inc. Investors with Large Losses They Have Until Monday May 4th to Seek Lead Plaintiff RoleA class action lawsuit has been filed against Aquestive Therapeutics for allegedly misleading investors about FDA approval prospects for its Anaphylm drug. The company failed to disclose FDA-identified deficiencies that precluded approval by the January 31, 2026 PDUFA date. Following the January 9, 2026 announcement of these deficiencies, Aquestive's stock price plummeted 37% from $6.21 to $3.91 per share. Investors who purchased shares between June 16, 2025 and January 8, 2026 have until May 4, 2026 to apply as lead plaintiff.GlobeNewswire Inc. · Apr 30, 2026

Portnoy Law Firm Announces Class Action on Behalf of Aquestive Therapeutics, Inc. InvestorsThe Portnoy Law Firm has announced a class action lawsuit against Aquestive Therapeutics on behalf of investors who purchased securities between June 16, 2025 and January 8, 2026. The lawsuit alleges that Aquestive made false statements about its Anaphylm drug approval prospects and failed to disclose FDA-identified deficiencies in the NDA application. Following the January 9, 2026 disclosure of these deficiencies, Aquestive's stock price fell more than 37%. The deadline for filing a lead plaintiff motion is May 4, 2026.GlobeNewswire Inc. · Apr 28, 2026

Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Aquestive Therapeutics and its officers for alleged securities fraud. The complaint alleges that defendants made materially false statements about the timeline for FDA approval of their Anaphylm drug and concealed significant human factors risks related to the sublingual film product that could impact regulatory approval.GlobeNewswire Inc. · Apr 27, 2026

AQST DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQSTRosen Law Firm is encouraging investors who suffered losses in securities class action lawsuits against Aquestive Therapeutics, Babcock & Wilcox Enterprises, and Snowflake Inc. to secure legal counsel before upcoming deadlines. The firm is seeking lead plaintiffs for cases involving alleged false statements and disclosure failures.GlobeNewswire Inc. · Apr 26, 2026

Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Aquestive Therapeutics and its officers for alleged securities fraud. The complaint alleges that defendants made materially false statements regarding the timeline for FDA approval of their Anaphylm drug and concealed significant human factors risks related to the sublingual film product that could impact regulatory approval.GlobeNewswire Inc. · Apr 23, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Eos Energy Enterprises, Inc. Of Class Action Lawsuit and Upcoming Deadlines – EOSEPomerantz Law Firm has filed class action lawsuits against Eos Energy Enterprises, Nektar Therapeutics, and Aquestive Therapeutics for alleged securities fraud. Eos Energy's stock fell 39.44% after missing earnings estimates significantly, with the company citing production issues and quality control problems.GlobeNewswire Inc. · Apr 21, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQSTPomerantz Law Firm has filed class action lawsuits against Aquestive Therapeutics, Eos Energy Enterprises, and Nektar Therapeutics, alleging securities fraud and unlawful business practices. The lawsuit against Aquestive was triggered by an FDA letter identifying deficiencies in the Anaphylm NDA review, causing the stock to drop 37% on January 9, 2026. Investors have until May 4, 2026, to request Lead Plaintiff status.GlobeNewswire Inc. · Apr 21, 2026

to start trading

AQ

AQSTAquestive Therapeutics, Inc. Common Stock

AQST

Pay with—

Available Balance0.00

Your PositionYou don't own any AQST yet.

Related Tickers

Earnings